Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a
subpopulation of glioma stem cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), a histone …

Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes
associated with resistance to cisplatin-based chemotherapy. Enhancer of zeste homolog 2 …

The polycomb group (PcG) proteins are a subset of transcription regulators highly conserved
throughout evolution. Their principal role is to epigenetically modify chromatin landscapes …

Enhancer of Zeste Homologue 2 (EZH2) is the catalytic subunit of the polycomb repressive
complex 2 (PRC2) that is critical for determining cell identity. An epigenetic writer, EZH2 has …

Lysine methylation, catalyzed by protein lysine methyltransferases (PKMTs), is a central post-
translational modification regulating many signaling pathways. It has direct and indirect …

Due to its high occurrence and mortality rate, breast cancer has been studied from various
aspects as one of the cancer field's hot topics in the last decade. Epigenetic alterations are …

Summary Polycomb repressive complex 2 (PRC2-EZH2) methylates histone H3 at lysine 27
(H3K27) and is required to maintain gene repression during development. Misregulation of …

Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies
aimed to describe the genomic landscape of BC have underscored the relevance of …

Numerous changes in epigenetic mechanisms have been described in various types of
tumors. In search for new biomarkers, we investigated the expression of Polycomb-group …

Colorectal cancer (CRC) develops in part through the deregulation of different signaling
pathways, including activation of the WNT/β-catenin and PI3K/AKT pathways. Additionally …